Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

Bristol Myers Squibb’s schizophrenia drug Cobnefy failed to meet a primary goal in a phase 3 trial, possibly clouding the drug’s future development. The trial evaluated Cobnefy as an add-on therapy to ...

Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the ... the Cobenfy brand name for the treatment ...

Explore how LB Pharmaceuticals is revolutionizing the pharma industry with its innovative therapies for neuropsychiatric ...

In the months after 24-year-old D.J. was diagnosed with schizophrenia, he searched online for answers to questions that felt urgent and existential.